An improved DiaRD MTB interferon-gamma release assay for the diagnosis of Mycobacterium Tuberculosis infections.

Publication date: Apr 06, 2026

This study aimed to develop a DiaRD Mycobacterium tuberculosis interferon-gamma release assay (DiaRD MTB IGRA) and to evaluate its diagnostic performance in comparison with the QuantiFERON-TB Gold Plus (QFT-Plus) assay for the detection of MTB infection. The DiaRD MTB IGRA was developed and optimized by testing different concentrations of antigens/peptides in the TB1 and TB2 antigen tubes, as well as anti-IFN-γ antibody concentrations in the enzyme-linked immunosorbent assay (ELISA) microplates. The analytical performance of the improved assay, including sensitivity, linearity, and reproducibility, was assessed. For clinical validation, a total of 346 whole-blood samples were analyzed, comprising individuals with MTB infection (n = 80) and uninfected controls (n = 266), using both the DiaRD MTB IGRA and the QFT-Plus assay. The improved DiaRD MTB IGRA demonstrated a limit of detection (LoD) of 0. 219 IU/mL within a linear dynamic range of 0-10 IU/mL. Reproducibility testing showed an overall coefficient variation (CV) of ≤11. 4%. Among the 346 samples, 80 (23. 1%) tested positive by QFT-Plus, including 27 from patients with active tuberculosis (TB) disease and 53 from individuals with TB infection (TBI), while 266 (76. 9%) were negative. The improved DiaRD MTB IGRA demonstrated a sensitivity of 96. 3% and a specificity of 96. 2%. The positive predictive value (PPV), negative predictive value (NPV), and overall accuracy were 88. 5%, 98. 8%, and 96. 2%, respectively. The overall agreement between the two assays was 93. 7% (_705 = 0. 90; 95% CI: 0. 84-0. 95), with no statistically significant difference observed (p = 0. 092). In conclusion, the improved DiaRD MTB IGRA showed good diagnostic performance and agreement with the comparator kit, suggesting that it may be useful for the detection of MTB infection.

Semantics

Original Article